Access
Dispensing sites, which include pharmacies, doctors’ offices, clinics, hospitals, urgent care centers, and local health departments, should contact their state’s department of health or their eligible jurisdiction’s department of health for ordering instructions.
Under Emergency Use Authorization, state health authorities will determine which dispensing sites will receive the product. To find dispensing sites that may be able to fill a prescription for U.S. Government-procured COVID-19 therapeutics, please refer to the resources below:
Contact the Merck National Service Center 1-800-672-6372 to learn about dispensing sites.
bThis link will take you to a database that is owned and operated by HHS. Merck is not responsible for the content or maintenance of this site.
How LAGEVRIO is supplied
NDC: 00006-5055-06
Bottles contain 40 (200 mg) oral capsules.
Expiration information
will vary by lot. Please refer to bottle.
Access FAQs
The U.S. government is currently allocating the product. Dispensing sites should contact their state’s department of health or their eligible jurisdiction’s department of health for ordering instructions.
AmerisourceBergen will only ship what is allocated by the states. Ordering facilities that do not receive all the product they requested will have to contact their state's health department or eligible jurisdiction's health department regarding any additional quantities available.
Please contact your state’s or eligible jurisdiction’s department of health for ordering instructions.
No. Please set up an account with your state’s or eligible jurisdiction’s department of health, which will be placing orders for the time being.
Yes. Under the Emergency Use Authorization, LAGEVRIO may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which LAGEVRIO belongs (i.e., anti-infectives).
Yes. To fill a prescription for LAGEVRIO, patients require positive results from a direct SARS-CoV-2 viral test.
Before prescribing LAGEVRIO, please read the accompanying Fact Sheet for Healthcare Providers, including Mandatory Requirements for Administration of LAGEVRIO Under Emergency Use Authorization. The FDA Letter of Authorization and the Fact Sheet for Patients and Caregivers are also available.
EUA=emergency use authorization; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
References: 1. LAGEVRIO™ (molnupiravir) emergency use authorization letter. US Food & Drug Administration. 2022. 2. Fact sheet for healthcare providers: emergency use authorization for LAGEVRIO™ (molnupiravir) capsules. Merck & Co., Inc. 2022. 3. Fact sheet for patients and caregivers emergency use authorization (EUA) of LAGEVRIO™ (molnupiravir) capsules for coronavirus disease 2019 (COVID-19). Merck & Co., Inc. 2022.